Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II
Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for ...
Armed robbery in Revesby12d
Immutep, Monash Reveal LAG-3 Binding to MHC Class II
Clinical-stage company Immutep (ASX:IMM) has announced new findings published in Science Immunology that resolve how human ...
Morningstar12d
Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II
Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a ... preferential binding to a subset of MHC Class II molecules on antigen-presenting cells ...
Immutep, Monash University announce publication on human LAG-3
Immutep (IMMP) announces new findings published in Science Immunology that resolve how human lymphocyte activation gene 3 binds to its main ...
EurekAlert!16d
Unlocking the potential to better target cancer with immunotherapy
Cancer immunotherapy has revolutionised treatment for patients, whereby the body’s own immune system is harnessed to destroy ...
Pharmabiz11d
Merck to discontinue phase 3 KeyVibe-003 & KeyVibe-007 trials of vibostolimab and favezelimab FDCs with pembrolizumab in certain patients with NSCLC
Merck to discontinue phase 3 KeyVibe-003 & KeyVibe-007 trials of vibostolimab and favezelimab FDCs with pembrolizumab in certain patients with NSCLC: Rahway, New Jersey Wednesday, ...